Drug Pricing Report Shows Limits of Transparency Push

This morning we're bringing you an article from the Wall Street Journal that highlights Vermont's recent drug price hikes. Vermont just recently passed the first law of its kind that requires drug manufacturers to justify these massive price increases. 

WSJ writes, "The first report, issued this month, identified 10 drugs. They included Mylan NV's EpiPen allergy treatment, whose price rose about 205% over the past five years; Sanofi's SA's Lantus insulin, up 90%; and AbbVie Inc.'s rheumatoid-arthritis treatment Humira, up 114%." 

Learn more about these reports by reading the full article HERE! 

HORIZON Health Ventures is a healthcare cost management solutions company used by insurance brokers, employee benefit consultants, third-party administrators, insurance companies, and associations, to bring proven thought leadership and strategy to the management of their clients healthcare costs. To learn more about HHV and their services, please visit http://horizonhealthventures.com/